Sanofi Consumer Healthcare India Limited has informed the Exchange about Copy of Newspaper Publication for Unaudited Financial Results for the quarter and half year ended 30th June 2025
SANOFICONR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi Consumer Healthcare India has informed the exchanges that its unaudited financial results for the quarter and half year ended 30 June 2025 were published in Business Standard and Sakal newspapers on 6 August 2025, in line with SEBI listing rules. The results were approved by the board on 4 August 2025 after review by the audit committee. Total income from operations for Q1 FY26 stood at ₹607 million, more than double the ₹290 million reported in Q1 FY25. For H1 FY26, total income was ₹1,107 million versus ₹917 million in H1 FY25, reflecting roughly 21% growth. Earnings per share (basic and diluted) for Q1 FY26 came in at ₹26.36, sharply higher than ₹12.58 in the year-ago quarter. This filing is essentially a regulatory compliance intimation accompanying the newspaper publication.
No fresh information for shareholders — the underlying results were already approved by the board on 4 August and likely priced in. The strong YoY jump in revenue and EPS suggests healthy business momentum, but investors should look at the detailed results filed with BSE/NSE for margin and segment clarity before reacting.